Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | terminated | Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer(RITCOLON) | terminated | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT01759238 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer(OLGA) | terminated | Phase 2 | 1 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | terminated | Phase 2 | 154 | MorphotekINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03099486 | Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC | terminated | Phase 2 | 2 | Fox Chase Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00321100 | Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab | terminated | Phase 2 | 23 | Fox Chase Cancer CenterOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02465593 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma(GCC 1314) | terminated | Phase 2 | 3 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT01505166 | Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases(FANG-CLM) | terminated | Phase 2 | 3 | Gradalis, Inc.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT02173990 | Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).(PULSAR) | terminated | Phase 2 | 40 | Centre Oscar LambretOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00314353 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | terminated | Phase 2 | 7 | NSABP Foundation IncNETWORK | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02851004 | Special Combination of BBI608 and Pembrolizumab | terminated | Phase 1 / Phase 2 | 55 | Takayuki YoshinoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01437514 | Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer | terminated | Phase 2 / Phase 3 | 410 | West China HospitalOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03311750 | Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer(A-REPEAT) | terminated | Phase 2 | 23 | Hellenic Cooperative Oncology GroupOTHER | 2 | Jun 7, 2021 | clinicaltrials |
| NCT02448810 | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | terminated | Phase 2 | 115 | Baxalta now part of ShireINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03158610 | Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer | terminated | Phase 2 / Phase 3 | 20 | Ruijin HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT02117466 | Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer(IMPACT-CRC) | terminated | Phase 1 / Phase 2 | 85 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT00005944 | Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer | terminated | Phase 2 | — | UNICANCEROTHER | 2 | Feb 17, 2021 | clinicaltrials |
| NCT03149679 | The p53 Colorectal Cancer Trial | terminated | Phase 2 | 12 | Haukeland University HospitalOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03170115 | Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer(ICAR) | terminated | Phase 2 | 25 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00986440 | Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy | terminated | Phase 2 | 84 | Daiichi SankyoINDUSTRY | 9 | Nov 5, 2020 | clinicaltrials |
| NCT02010567 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00671645 | Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy | terminated | Phase 2 | 8 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03549338 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | terminated | Phase 2 | 2 | Symphogen A/SINDUSTRY | 4 | Sep 28, 2020 | clinicaltrials |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02652702 | Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients(STAPLER) | terminated | Phase 2 | 60 | Zhejiang UniversityOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01609231 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | terminated | Phase 2 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 4, 2020 | clinicaltrials |
| NCT00602329 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | terminated | Phase 2 | 5 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00353457 | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | terminated | Phase 2 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer(McCAVE) | terminated | Phase 2 | 197 | Hoffmann-La RocheINDUSTRY | 7 | Mar 25, 2020 | clinicaltrials |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Georgetown UniversityOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT01057017 | First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01669720 | Adjuvant Aflibercept for Metastatic Colorectal Cancer(C261) | terminated | Phase 2 | 10 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer(276) | terminated | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00955240 | Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer | terminated | Phase 2 | 16 | UNICANCEROTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01993472 | Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer(AGCRC-013) | terminated | Phase 2 | 308 | Gu YanhongOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01532804 | 2nd-line Treatment of Metastatic Colorectal Cancer(BEVATOMOX) | terminated | Phase 2 | 83 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT00580073 | Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Oct 6, 2022source: clinicaltrials